KR940003553A - 지방산을 함유하는 조성물 및 지방산을 이용한 처지방법 - Google Patents
지방산을 함유하는 조성물 및 지방산을 이용한 처지방법 Download PDFInfo
- Publication number
- KR940003553A KR940003553A KR1019930016204A KR930016204A KR940003553A KR 940003553 A KR940003553 A KR 940003553A KR 1019930016204 A KR1019930016204 A KR 1019930016204A KR 930016204 A KR930016204 A KR 930016204A KR 940003553 A KR940003553 A KR 940003553A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- gamma
- linolenic acid
- dihomo
- gla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title claims abstract 4
- 229930195729 fatty acid Natural products 0.000 title claims abstract 4
- 239000000194 fatty acid Substances 0.000 title claims abstract 4
- 150000004665 fatty acids Chemical class 0.000 title claims abstract 4
- 238000000034 method Methods 0.000 title claims 6
- 238000007665 sagging Methods 0.000 title 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract 16
- 235000020778 linoleic acid Nutrition 0.000 claims abstract 16
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract 16
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract 15
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract 15
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract 15
- 235000004626 essential fatty acids Nutrition 0.000 claims abstract 10
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052791 calcium Inorganic materials 0.000 claims abstract 7
- 239000011575 calcium Substances 0.000 claims abstract 7
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims abstract 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims abstract 5
- 238000010521 absorption reaction Methods 0.000 claims abstract 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims abstract 5
- 241001465754 Metazoa Species 0.000 claims abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract 3
- 206010006956 Calcium deficiency Diseases 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 7
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 7
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 7
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- YIYBQIKDCADOSF-UHFFFAOYSA-N pent-2-enoic acid Chemical compound CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fertilizers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9217780.7 | 1992-08-21 | ||
| GB929217780A GB9217780D0 (en) | 1992-08-21 | 1992-08-21 | Fatty acid treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR940003553A true KR940003553A (ko) | 1994-03-12 |
Family
ID=10720716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930016204A Ceased KR940003553A (ko) | 1992-08-21 | 1993-08-20 | 지방산을 함유하는 조성물 및 지방산을 이용한 처지방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5618558A (https=) |
| EP (1) | EP0585026B1 (https=) |
| JP (1) | JPH06157303A (https=) |
| KR (1) | KR940003553A (https=) |
| CN (1) | CN1049334C (https=) |
| AT (1) | ATE159856T1 (https=) |
| AU (1) | AU666747B2 (https=) |
| CA (1) | CA2104567A1 (https=) |
| DE (1) | DE69315020T2 (https=) |
| DK (1) | DK0585026T3 (https=) |
| ES (1) | ES2110060T3 (https=) |
| GB (1) | GB9217780D0 (https=) |
| GR (1) | GR3025898T3 (https=) |
| MY (1) | MY109928A (https=) |
| NO (1) | NO306655B1 (https=) |
| NZ (1) | NZ248422A (https=) |
| RU (1) | RU2122409C1 (https=) |
| SG (1) | SG80536A1 (https=) |
| TW (1) | TW323230B (https=) |
| ZA (1) | ZA935976B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9325445D0 (en) | 1993-12-13 | 1994-02-16 | Cortecs Ltd | Pharmaceutical formulations |
| GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
| EP0711503A3 (en) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
| US5804210A (en) * | 1996-08-07 | 1998-09-08 | Wisconsin Alumni Research Foundation | Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein |
| GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
| WO1999003456A2 (en) * | 1997-07-16 | 1999-01-28 | Societe Des Produits Nestle S.A. | Method for prophylaxis or treatment of bone density loss |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| US6479545B1 (en) * | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| EG22407A (en) * | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
| ES2289097T3 (es) * | 2001-03-15 | 2008-02-01 | Dsm Ip Assets B.V. | Composicion para la prevencion de la osteoporosis consistente de una combinacion de isoflavonas y acidos grasos poliinsaturados. |
| EP1380293A4 (en) * | 2001-03-30 | 2009-03-18 | Nisshin Oillio Group Ltd | MEANS TO IMPROVE BONE MATERIAL CHANGE |
| US7098352B2 (en) * | 2001-11-16 | 2006-08-29 | Virtus Nutrition Llc | Calcium salt saponification of polyunsaturated oils |
| EP1711173A2 (en) * | 2003-12-31 | 2006-10-18 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof |
| CA2569230C (en) * | 2004-04-30 | 2014-12-02 | Nutriscience Technology, Inc. | Polyunsaturated fatty acid monovalent and divalent metal salt synthesis |
| US20090182050A1 (en) * | 2005-10-07 | 2009-07-16 | Ocean Nutrition Canada, Ltd. | Salts of Fatty Acids and Methods of Making and Using thereof |
| DE102007022694A1 (de) * | 2007-05-11 | 2008-11-13 | Humana Milchunion Eg | Milchfett-Milchprotein-Zusammensetzung zur Verbesserung der Calcium-Aufnahme |
| DE102007039310A1 (de) * | 2007-08-13 | 2009-02-19 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Zusammensetzung zur Prophylaxe und Behandlung von Osteoporose |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| WO2010028067A1 (en) | 2008-09-02 | 2010-03-11 | Amarin Corporation Plc | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| KR101383006B1 (ko) | 2009-02-10 | 2014-04-08 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
| CN106074486A (zh) | 2009-06-15 | 2016-11-09 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| RU2606853C2 (ru) * | 2010-03-04 | 2017-01-10 | Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания |
| US8178707B2 (en) | 2010-03-25 | 2012-05-15 | Jost Chemical Company | Co-precipitated salts of fatty acids |
| CN101978949A (zh) * | 2010-11-16 | 2011-02-23 | 王京南 | γ-亚麻酸酯脂肪乳静脉注射液及其制造方法 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| EP4338805B1 (en) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US8728546B1 (en) | 2013-03-15 | 2014-05-20 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer, cardiovascular diseases and inflammation |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US9682055B2 (en) | 2014-06-04 | 2017-06-20 | Dignity Sciences Limted | Pharmaceutical compositions comprising DGLA and use of same |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| CA3024191C (en) * | 2016-06-01 | 2024-05-28 | Nestec S.A. | Composition for use in the prophylaxis of allergic disease |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| KR20210110890A (ko) | 2018-09-24 | 2021-09-09 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1417119A (en) * | 1972-11-30 | 1975-12-10 | Thiele G H | Process for treating bones |
| GB8621816D0 (en) * | 1986-09-10 | 1986-10-15 | Efamol Ltd | Therapeutic composition |
| JPH0625057B2 (ja) * | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | 骨形成促進剤 |
| GB9112052D0 (en) * | 1991-06-05 | 1991-07-24 | Efamol Holdings | Fatty acid treatment |
-
1992
- 1992-08-21 GB GB929217780A patent/GB9217780D0/en active Pending
-
1993
- 1993-08-16 JP JP5202396A patent/JPH06157303A/ja active Pending
- 1993-08-16 SG SG9605801A patent/SG80536A1/en unknown
- 1993-08-16 US US08/106,989 patent/US5618558A/en not_active Expired - Fee Related
- 1993-08-16 ES ES93306444T patent/ES2110060T3/es not_active Expired - Lifetime
- 1993-08-16 AT AT93306444T patent/ATE159856T1/de not_active IP Right Cessation
- 1993-08-16 EP EP93306444A patent/EP0585026B1/en not_active Expired - Lifetime
- 1993-08-16 DK DK93306444.6T patent/DK0585026T3/da active
- 1993-08-16 ZA ZA935976A patent/ZA935976B/xx unknown
- 1993-08-16 DE DE69315020T patent/DE69315020T2/de not_active Expired - Fee Related
- 1993-08-16 AU AU44666/93A patent/AU666747B2/en not_active Ceased
- 1993-08-17 NZ NZ248422A patent/NZ248422A/en unknown
- 1993-08-20 NO NO932983A patent/NO306655B1/no not_active IP Right Cessation
- 1993-08-20 RU RU93049153A patent/RU2122409C1/ru active
- 1993-08-20 CA CA002104567A patent/CA2104567A1/en not_active Abandoned
- 1993-08-20 KR KR1019930016204A patent/KR940003553A/ko not_active Ceased
- 1993-08-21 MY MYPI93001672A patent/MY109928A/en unknown
- 1993-08-21 CN CN93118320A patent/CN1049334C/zh not_active Expired - Fee Related
- 1993-08-23 TW TW082106797A patent/TW323230B/zh active
-
1998
- 1998-01-14 GR GR980400071T patent/GR3025898T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ248422A (en) | 1997-06-24 |
| JPH06157303A (ja) | 1994-06-03 |
| TW323230B (https=) | 1997-12-21 |
| CA2104567A1 (en) | 1994-02-22 |
| SG80536A1 (en) | 2001-05-22 |
| HK1000997A1 (en) | 1998-05-15 |
| ATE159856T1 (de) | 1997-11-15 |
| MY109928A (en) | 1997-09-30 |
| ZA935976B (en) | 1994-03-14 |
| NO932983D0 (no) | 1993-08-20 |
| GB9217780D0 (en) | 1992-10-07 |
| AU666747B2 (en) | 1996-02-22 |
| US5618558A (en) | 1997-04-08 |
| EP0585026A1 (en) | 1994-03-02 |
| GR3025898T3 (en) | 1998-04-30 |
| DE69315020D1 (de) | 1997-12-11 |
| ES2110060T3 (es) | 1998-02-01 |
| CN1049334C (zh) | 2000-02-16 |
| CN1091285A (zh) | 1994-08-31 |
| RU2122409C1 (ru) | 1998-11-27 |
| EP0585026B1 (en) | 1997-11-05 |
| DK0585026T3 (da) | 1998-06-02 |
| AU4466693A (en) | 1994-02-24 |
| DE69315020T2 (de) | 1998-04-16 |
| NO306655B1 (no) | 1999-12-06 |
| NO932983L (no) | 1994-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR940003553A (ko) | 지방산을 함유하는 조성물 및 지방산을 이용한 처지방법 | |
| KR0129666B1 (ko) | 필수지방산 조성물 | |
| KR940018089A (ko) | 내부조직의 방사선 손상에 대한 예방 및 처치방법 | |
| KR930000114A (ko) | 지방산을 이용한 치료 | |
| US9084801B2 (en) | Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs | |
| RU93049153A (ru) | Лечение жирными кислотами | |
| KR920000324A (ko) | 필수 지방산 처리법 | |
| PL190181B1 (pl) | Zastosowanie oleju zawierającego kwas eikozapentaenowy (KEP) i/lub kwas stearydonowy (KS) oraz preparat farmaceutyczny zawierający olej | |
| JPH02104522A (ja) | 脂肪酸を含有する医薬用組成物 | |
| ES2093695T3 (es) | Composicion para el tratamiento de trastornos inflamatorios del intestino. | |
| ES2107663T3 (es) | Empleo de una emulsion que contiene acidos grasos omega-3 en la fabricacion de un medicamento a administrar por via parenteral para el tratamiento de las enfermedades inflamatorias. | |
| DE69114498D1 (de) | Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen. | |
| RU2000132310A (ru) | Применение продуктов на основе магния для лечения или профилактики опухолевых и аутоиммунных заболеваний | |
| KR920703041A (ko) | 통증을 수반하는 염증성 또는 알레르기성 질환치료에 사용되는 성분물과 그 방법 | |
| US8206759B2 (en) | Method of reducing blood cholesterol and triglyceride levels using combinations of vasoprotective agent | |
| EP0147741A3 (en) | Pharmaceutical composition with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of diseases of the stomach and the intestines | |
| KR940003552A (ko) | 지방산을 이용한 석회화 예방 및 치료방법 | |
| KR970705988A (ko) | 연골 조직의 이상에 기인하는 질환의 예방 또는 치료제(Preventive or remedy for diseases caused by abnormalities in cartilage tissues) | |
| EP1091659B1 (de) | Orale darreichungsform | |
| WO2006040324A1 (de) | Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung | |
| KR920702225A (ko) | 약학 조성물 | |
| WO2011109586A1 (en) | Substances for promoting healthy joint function comprising omega-3 polyunsaturated fatty acids or derivatives thereof, undenatured type ii collagen and, optionally, glucosamine sulfate | |
| IL73849A0 (en) | Pharmaceutical compositions containing phospholipids and oxicam derivatives and their production | |
| KR960013433B1 (ko) | 리튬염 함유 제약 조성물 | |
| RU99106551A (ru) | Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930820 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19980819 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19930820 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000614 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20000927 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20000614 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |